Tests a digital platform for patients' feedback on psychiatric care
Studies a digital tool that collects patient experiences in people with mental health conditions.
Key facts
- Who runs it
- Assistance Publique Hopitaux De Marseille
- Where
- Marseille, FranceSee the site
- Trial code
- Registry title
- MonPsy&Moi: A Digital Platform for Collecting Patient-Reported Experience and Outcome Measures in Psychiatry
- Status
- Not yet recruiting
- People taking part
- 23,660 people, planned
- Started
- 2 Feb 2025
- Planned end
- 21 Sept 2026
- Type of study
- Observational
- Record updated
- 10 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 living in France who receive psychiatric care for schizophrenia, bipolar disorder or major depression.
- Age
- 18 to 65 years
- Sex
- All sexes
- Disease stage
- A confirmed diagnosis of a schizophrenia spectrum disorder, bipolar disorder or major depressive disorder, with care at one of the 12 taking-part psychiatric facilities.
Main reasons for not taking part
- Main diagnosis of an organic mental disorder, such as dementia, stroke or traumatic brain injury
- Being deprived of liberty by a court decision, for example people in prison
- No valid email address
- Cannot read and understand French
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Residing in France. Age between 18 and 65 years at the time of inclusion; Receiving care in one of the 12 participating psychiatric facilities, with a confirmed diagnosis of:; Schizophrenia Spectrum Disorders (e.g., schizophrenia, schizoaffective disorder); Bipolar Disorders. Major Depressive Disorders. A valid email address. Ability to read and understand French. Non-opposition to participating in the study (based on informed consent)
Who cannot take part
- Primary diagnosis of an organic mental disorder, including:; Dementia. Stroke. Traumatic brain injury. Individuals deprived of liberty by judicial decision (e.g., incarcerated patients)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in France
- Assistance Publique Hôpitaux de MarseilleMarseille, FranceContact: Laurent BOYER, PrNo longer taking part
About the trial
What the trial wants to find out
Mental health disorders, with a 30% annual prevalence rate, are a leading cause of disability and reduced life expectancy. Despite their impact, patient-reported experience measures (PREMs) and outcome measures (PROMs) are underutilized in psychiatry. MonPsy\&Moi®, a digital platform funded by ATIH and DGOS, addresses this gap by providing a user-friendly tool to assess patient experiences and outcomes in real-time, aiming to improve the quality of psychiatric care across France.
Read full original descriptionShow less
The study consists of two stages:
Stage 1 (No Feedback): MonPsy\&Moi® is deployed across 12 psychiatric facilities, collecting patient data without feedback to clinicians. Objectives include assessing implementation feasibility, validating adaptive questionnaires (PREMIUM), and identifying predictors of patient outcomes, such as relapse and healthcare utilization.
Stage 2 (With Feedback): Focuses on patients with severe mental illnesses (schizophrenia, bipolar disorders, and major depressive disorders). This stage evaluates the impact of providing PREMs/PROMs feedback to clinicians on relapse rates, healthcare costs, and overall patient outcomes.
MonPsy\&Moi® uses adaptive questionnaires tailored to psychiatric care, covering key domains such as dignity, information, interpersonal relationships, care environment, and treatment. It also evaluates health-related quality of life, including psychological well-being, autonomy, self-esteem, and social relationships. The platform integrates with national healthcare databases (SNDS) to enhance data analysis and predict patient trajectories.
The study will involve over 22,000 participants in Stage 1 and 1,100 participants in Stage 2, using a quasi-experimental design to compare feedback and non-feedback strategies. Results aim to demonstrate the feasibility, acceptability, and efficacy of MonPsy\&Moi® in improving mental health outcomes and guiding national psychiatric care policies.
By empowering patients and clinicians with actionable insights, MonPsy\&Moi® aspires to set a new standard for patient-centered mental healthcare in real-world settings
The group in the trial
- Psychiatric patients
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- MonPsyMoi: Etude Des Conditions d'implémentation et de l'Impact de la Plateforme Digitale française de Recueil de l'expérience Patient en Psychiatrie (Modules Avec et Sans " Feedback ")
- Plain-language title
- Tests a digital platform for patients' feedback on psychiatric careGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06818227, who can take part
- Record updated
- 10 February 2025